Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27

Journal of Immunology

Volumn 173, Issue 10, 2004, Pages 6465-6471

  Goldberg, Ruth ^a   Zobar, Yaniv ^a   Wildbaum, Gizi ^a   Geron, Yifat ^a   Maor, Gila ^a   Karin, Nathan ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOKINE; ENCEPHALITOGENIC PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 27; NEUTRALIZING ANTIBODY; POLYPEPTIDE; PROTEIN P28; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; INTERFERON PRODUCTION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 8444235333     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.10.6465     Document Type: Article

References (46)

1. Alvord, E. C. J., M. W. Kies, and A. J. Suckling. 1984. Experimental allergic encephalomylitis: a useful model for multiple sclerosis. In Progress in Clinical and Biological Research. Vol. 146. E. C. J. Alvord, M. W. Kies, and A. J. Suckling, eds. Liss. New York, p. 1.
2. MacFarlin, D., and H. MacFarland. 1983. Multiple sclerosis. N. Engl. J. Med. 307:1183.
3. O'Garra, A., and K. Murphy. 1994. Role of cytokines in determining T-lymphocyte function. Curr. Opin. Immunol. 6:458.
4. Mosmann, T. R., and R. L. Coffman. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 9:145.
5. Chen, Y., V. K. Kuchroo, J. Inobe, D. Hafler, and H. L. Weiner. 1994. Regulatory T-cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265:1237.
6. Fukaura, H., S. C. Kent, M. J. Pietrusewicz, S. J. Khoury, H. L. Weiner, and D. A. Hafler. 1996. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-β1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest. 98:70.
7. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737.
8. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:389.
9. Leonard, J. P., K. E. Waldburger, and S. J. Goldman. 1995. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181:381.
10. Wildbaum, G., N. Netzer, and N. Karin. 2002. Plasmid DNA encoding IFN-γ-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J. Immunol. 168:5885.
11. Wildbaum, G., S. Youssef, N. Grabie, and N. Karin. 1998. Neutralizing antibodies to IFN-γ-inducing factor prevent experimental autoimmune encephalomyelitis. J. Immunol. 161:6368.
12. Gracie, J. A., R. J. Forsey, W. L. Chan, A. Gilmour, B. P. Leung, M. R. Greer, K. Kennedy, R. Carter, X. Q. Wei, D, Xu, et al. 1999. A proinflammatory role for IL-18 in rheumatoid arthritis. J. Clin. Invest. 104:1393.
13. Joosten, L. A., F. A. van De Loo, E. Lubberts, M. M. Helsen, M. G. Netea, J. W. van Der Meer, C. A. Dinarello, and W. B. van Den Berg. 2000. An IFN-γ-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J. Immunol. 165:6553.
14. Salomon, I., N. Netzer, G. Wildbaum, S. Schif-Zuck, G. Maor, and N. Karin. 2002. Targeting the function of IFN-γ-inducible protein 10 suppresses ongoing adjuvant arthritis. J. Immunol. 169:2685.
15. Butler, D. M., A. M. Malfait, R. N. Maini, F. M. Brennan, and M. Feldmann. 1999. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur. J. Immunol. 29:2205.
16. + T cells. Immunity 16:779.
17. Trinchieri, G., S. Pflanz, and R. A. Kastelein. 2003. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19:641.
18. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133.
19. Brombacher, F., R. A. Kastelein, and G. Alber. 2003. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 24:207.
20. Robinson, D. S., and A. O'Garra. 2002. Further checkpoints in Th1 development. Immunity 16:755.
21. Hibbert, L., S. Pflanz, R. De Waal Malefyt, and R. A. Kastelein. 2003. IL-27 and IFN-α signal via Stat1 and Stat3 and induce T-Bet and IL-12Rβ2 in naive T cells. J. Interferon Cytokine. Res. 23:513.
22. + T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA 100:15047.
23. Takeda, A., S. Hamano, A. Yamanaka, T. Hanada, T. Ishibashi, T. W. Mak, A. Yoshimura, and H. Yoshida. 2003. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170:4886.
24. Larousserie, F., S. Pflanz, A. Coulomb-L'Hermine, N. Brousse, R. Kastelein, and O. Devergne. 2004. Expression of IL-27 in human Th1-associated granulomatous diseases. J. Pathol. 202:164.
25. Goldberg, R., G. Wildbaum, Y. Zohar, G. Maor, and N. Karin. 2004. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J. Immunol. 173:1171.
26. Youssef, S., G. Wildbaum, G. Maor, N. Lanir, A. Gour-Lavie, N. Grabie, and N. Karin. 1998. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J. Immunol. 161:3870.
27. Wildbaum, G., and N. Karin. 1999. Augmentation of natural immunity to a proinflammatory cytokine (TNF-α) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis. Gene. Ther. 6:1128.
28. Youssef, S., G. Wildbaum, and N. Karin. 1999. Prevention of experimental autoimmune encephalomyelitis by MIP-1α and MCP-1 naked DNA vaccines. J. Autoimmun. 13:21.
29. Wildbaum, G., S. Youssef, and N. Karin. 2000. A targeted DNA vaccine augments the natural immune response to self TNF-α and suppresses ongoing adjuvant arthritis. J. Immunol. 165:5860.
30. Wildbaum, G., J. Westermann, G. Maor, and N. Karin. 2000. A targeted DNA vaccine encoding fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. J. Clin. Invest. 106:671.
31. Youssef, S., G. Maor, G. Wildbaum, N. Grabie, A. Gour-Lavic, and N. Karin. 2000. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J. Clin. Invest. 106:361.
32. Wildbaum, G., M. Nahir, and N. Karin. 2003. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 19:679.
33. Blank, M., I. Krause, G. Wildbaum, N. Karin, and Y. Shoenfeld. 2003. TNFα DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome. Lupus 12:546.
34. Mendel, I., N. Kerlero de Rosbo, and A. Ben-Nun. 1995. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor Vβ expression of encephalitogenic T cells. Eur. J. Immunol. 25:1951.
35. Tompkins, S. M., J. Padilla, M. C. Dal Canto, J. P. Ting, L. Van Kaer, and S. D. Miller. 2002. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J. Immunol. 168:4173.
36. Wildbaum, G., N. Netzer, and N. Karin. 2002. Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading. J. Clin. Invest 110:701.
37. Brocke, S., K. Gijbels, M. Allegretta, I. Ferber, C. Piercy, T. Blankenstein, R. Martin, U. Utz, N. Karin, D. Mitchell, et al. 1996. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 379:343.
38. Min, B., K. L. Legge, C. Pack, and H. Zaghouani. 1998. Neonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon γ-mediated splenic anergy. J. Exp. Med. 188:2007.
39. Villarino, A., L. Hibbert, L. Lieberman, E. Wilson, T. Mak, H. Yoshida, R. A. Kastelein, C. Saris, and C. A. Hunter. 2003. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19:645.
40. 1 integrin. Nature 356:63.
41. Miller, D. H., O. A. Khan, W. A. Sheremata, L. D. Blumhardt, G. P. Rice, M. A. Libonati, A. J. Willmer-Hulme, C. M. Dalton, K. A. Miszkiel, and P. W. O'Connor. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348:15.
42. Bauer, J., M. Bradl, W. F. Hickley, S. Forss-Petter, H. Breitschopf, C. Linington, H. Wekerle, and H. Lassmann. 1998. T-cell apoptosis in inflammatory brain lesions: destruction of T cells does not depend on antigen recognition. Am. J. Pathol. 153:715.
43. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
44. Khoruts, A., S. D. Miller, and M. K. Jenkins. 1995. Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by elfector Th1 cells. J. Immunol. 155:5011.
45. Pedotti, R., D. Mitchell, J. Wedemeyer, M. Karpuj, D. Chabas, E. M. Hattab, M. Tsai, S. J. Galli, and L. Steinman. 2001. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat. Immunol. 2:216.
46. + T cells via ELISPOT in PBMC: cognate vs. nonspecific production of the cytokine. J. Immunol. Methods 279:111.